Researchers have slowed the spread of a type of non-small cell lung cancer in mice by neutralising a protein that would otherwise cause tumour growth.
List view / Grid view
Filter the results
A study has revealed five new signalling processes in GPCR receptors on cells that have high therapeutic potential.
A simple and direct method of introducing lipids into protein has been developed using palladium as a catalyst.
A new drug discovery strategy predicts the clinical actions of new compounds to promote desired clinical responses and avoid side effects.
Application note: Faster and more reliable quantification of oligonucleotide interaction with human serum albumin using MST
Antisense oligonucleotides are an emerging therapeutic option for treating diseases with known genetic origin.
SB Drug Discovery shows the validation of fluorescence and automated electrophysiology assays designed to assess agonists, antagonists and allosteric modulators of these receptors, culminating in a high-throughput electrophysiology assay suited to assessing multiple GABAA receptor subtypes on a single assay plate.
Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application
This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.
Expert view: Tackling drug discovery inefficiencies requires diverse libraries, technologies with broader applicability and actionable insights
Inefficiencies in drug discovery are hard to ignore when despite ever-increasing investment in pharmaceutical research and development, the number of new drugs approved by the US Food and Drug Administration (FDA) remains low.
The relative failure of molecular target-based drug discovery has led to a return to phenotypic screening. Targets that are intracellular necessitate their drug ligands to pass through plasma membranes, where the protein:lipid ratio is often 3:1 by mass and at least 1:1 by area. The widespread view that most of…
Application note: NanoBRETTM assay for monitoring of ligand binding to GPCRs in live cells, using the CLARIOstar® and the PHERAstar® FS
Due to the crucial role of G protein-coupled receptors (GPCRs) in mediating cellular responses to external stimuli, these receptors have been and will remain a prime focus for medical research and the pharmaceutical industry for many years to come. Their importance is especially highlighted by the statistic that 30-50% of…
An integrated fragment-based approach, which reveals enzymatic inhibitors with potential therapeutic application, is the subject of this webinar.Taking place on 25 October 2018 at 3:00pm, the webinar is supported by NanoTemper Technologies.
Application note: NanoBRET™ assay quantitatively evaluates VEGF binding to the VEGFR2 in real-time in living cells
In this application note, we show how the signal of luciferase and fluorophore were acquired simultaneously with the PHERAstar microplate reader...
In this application note we will show how a cAMP BRET biosensor can be used to monitor ligand binding with the help of the CLARIOstar microplate reader...
Application note: CRISPR/Cas9 genome-edited cells express nanoBRET-donor that monitors protein interaction and trafficking
In this application note, BMG Labtech discuss how the Bioluminescence resonance energy transfer (BRET) is a versatile tool to study interactions and trafficking in proteins.
Researchers have discovered a significant new compound that helps to mobilise a type of T cell – invariant natural killer T (iNKT) cells – in the fight against disease.